Despite being the largest study to date that has evaluated outcomes of combined PD-L(1)/CTLA-4 blockade in HCC after failing anti-PD-(L)1 therapy, our cohort is small, which limits the generalizability of our findings and our ability to compare patient outcomes based on important clinical and demographic factors. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.